islatravir (MK-8591) / Merck (MSD)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
islatravir (MK-8591) / Merck (MSD)
Impower-022, NCT04644029 / 2021-001289-39: Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

Active, not recruiting
3
730
US, RoW
Islatravir, MK-8591, Placebo to FTC/TDF, FTC/TDF, TRUVADA™, Emtricitabine/Tenofovir disoproxil, Emtricitabine/Tenofovir disoproxil fumarate, Placebo to ISL
Merck Sharp & Dohme LLC
HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
07/23
07/24
Impower-024, NCT04652700 / 2020-003309-79: Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

Completed
3
494
Europe, Japan, US, RoW
ISL, MK-8591, FTC/TDF, Truvada, Emtricitabine/Tenofovir Disoproxil Fumarate, FTC/TAF, Descovy, Emtricitabine/Tenofovir Alafenamide, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF
Merck Sharp & Dohme LLC
HIV Preexposure Prophylaxis
08/23
08/23

Download Options